
TORONTO, Oct. 16 /CNW/ - Patheon Inc. (TSX: PTI) today announced that it has entered into an agreement with its lenders to amend certain financial covenants under its North American loan facilities. The amendment to the North American credit agreement establishes amended financial covenants, including trailing 12-month debt-to-EBITDA covenants. The amended covenants, to be satisfied monthly, cover a six-month period from October 31, 2006 to March 31, 2007, by which time Patheon intends to have implemented a long-term improvement to its capital structure. "With this amendment in place, Patheon has the financial flexibility to continue to operate our business effectively and in compliance with our loan agreements. At the same time, we will continue to pursue strategic alternatives that will serve the interests of our shareholders, clients, and employees," said Mr. Riccardo Trecroce, Chief Executive Officer, Patheon Inc. "We are making progress on the strategic review process announced last month, and we intend to complete this process during the period covered by the amendment to the credit agreement." As at September 30, 2006, US$252.4 million was outstanding under the North American loan facilities. As part of the amendment, the North American revolving loan facility was reduced from US$75 million to US$60 million. As at September 30, 2006, US$42.3 million was borrowed under this facility. The maximum amount that may be borrowed under this facility from time to time is a function of borrowing base calculations prescribed in the credit agreement, and is typically less than US$60 million. The Company had US$49 million of cash reserves as at September 30, 2006, and continues to be satisfied that it has sufficient liquidity to carry on its business in the ordinary course. About Patheon Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of more than 200 pharmaceutical and biotechnology companies. Caution Concerning Forward-Looking Statements This press release contains forward-looking statements which reflect management's expectations regarding Patheon's future growth, results of operations, performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as "plans", "expects" or "does not expect", "forecasts", "anticipates" or "does not anticipate", "believes", "intends" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved have been used to identify these forward- looking statements. Although the forward-looking statements contained in this press release reflect management's current assumptions based upon information currently available to management and what management believes to be reasonable assumptions, Patheon cannot be certain that actual results will be consistent with these forward-looking statements. Forward-looking statements necessarily involve significant known and unknown risks, assumptions and uncertainties that may cause Patheon's actual results, performance, prospects and opportunities in future periods to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things: the market demand for client products; dependence on key clients; the ability to identify and secure new contracts; regulatory matters, including compliance with pharmaceutical regulations; management of expanded operations; international operations risks; currency risks; competition; product liability claims; integration of new operations; financing risks; and interest rate risks. Although Patheon has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in the forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, and results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Except as otherwise stated, these forward-looking statements are made as of the date of this press release and, except as required by law, Patheon assumes no obligation to update or revise them to reflect new events or circumstances.